Ultragenyx Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Ultragenyx Pharmaceutical has a total shareholder equity of $353.8M and total debt of $878.4M, which brings its debt-to-equity ratio to 248.3%. Its total assets and total liabilities are $1.5B and $1.2B respectively.
Key information
248.3%
Debt to equity ratio
US$878.42m
Debt
| Interest coverage ratio | n/a |
| Cash | US$607.51m |
| Equity | US$353.83m |
| Total liabilities | US$1.18b |
| Total assets | US$1.54b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RARE *'s short term assets ($799.6M) exceed its short term liabilities ($285.0M).
Long Term Liabilities: RARE *'s short term assets ($799.6M) do not cover its long term liabilities ($899.5M).
Debt to Equity History and Analysis
Debt Level: RARE *'s net debt to equity ratio (76.6%) is considered high.
Reducing Debt: RARE *'s debt to equity ratio has increased from 0% to 248.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RARE * has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RARE * has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 06:25 |
| End of Day Share Price | 2024/10/16 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ultragenyx Pharmaceutical Inc. is covered by 37 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Michael Ulz | Baird |
| Huidong Wang | Barclays |